Skip to content
lifestyle.thenyctimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Decoy Therapeutics, Inc
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
September 29, 2026
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
September 22, 2026
/C O R R E C T I O N — Decoy Therapeutics, Inc/
September 22, 2026
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
September 22, 2026
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
September 22, 2026
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
August 3, 2026
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
July 27, 2026
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
July 15, 2026
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
June 26, 2026
Decoy Therapeutics’ CEO to Participate in hVIVO Capital Markets Day in London
June 8, 2026
1
2
Next Page
→